Insys Therapeutics Inc. (NASDAQ:INSY) Director John N. Kapoor purchased 5,000 shares of the company’s stock on the open market in a transaction that occurred on Friday, June 13th. The stock was purchased at an average price of $25.44 per share, with a total value of $127,200.00. Following the acquisition, the director now directly owns 15,991 shares in the company, valued at approximately $406,811. Insys Therapeutics Inc. (NASDAQ:INSY) net profit margin is 36.90% and weekly performance is 18.23%. On last trading day company shares ended up $29.70. Analysts mean target price for the company is $52.50. Insys Therapeutics Inc. (NASDAQ:INSY) distance from 50-day simple moving average (SMA50) is -8.05%.
On June 13, 2014, TG Therapeutics, Inc. (NASDAQ:TGTX) issued a press release announcing preliminary clinical results from its ongoing Phase 2 study of TG-1101 (ublituximab), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib (IMBRUVICA), the oral BTK inhibitor from Pharmacyclics/Janssen. TG Therapeutics, Inc. (NASDAQ:TGTX) shares fell -2.22% in last trading session and ended the day on $8.82. TGTX return on assets is -54.70%.TG Therapeutics, Inc. (NASDAQ:TGTX) quarterly performance is 20.82%.
On June 4, 2014, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) entered into the California Competes Tax Credit Allocation Agreement (the “Agreement”) with the California Governor’s Office of Business and Economic Development (“GO-Biz”). The Agreement, which will become effective if and when approved by the California Competes Tax Credit Committee, would award Ultragenyx a California Competes Tax Credit (the “Tax Credit”) in the amount of $2,100,000. The California Competes Tax Credit Committee is expected to consider approval of the Agreement at a public hearing scheduled for June 19, 2014. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares moved up 4.34% in last trading session and was closed at $42.58, while trading in range of $39.35 – $42.95. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) year to date (YTD) performance is 0.78%.
Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is set to join the broad-market Russell 3000(R) Index as well as the Russell 2000(R) , Russell Global and Russell Microcap(R) indexes when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27. Actinium Pharmaceuticals Inc. (NYSEMKT:ATNM) ended the last trading day at $11.05. Company weekly volatility is calculated as 5.16% and price to cash ratio as 47.89.Actinium Pharmaceuticals Inc. (NYSEMKT:ATNM) showed a negative weekly performance of -7.45%.
Shares of Acorda Therapeutics Inc. (NASDAQ:ACOR) , a biopharmaceutical company focused on developing therapies to treat multiple sclerosis, spinal cord injuries, and other central nervous system disorders, tumbled as much as 10% after announcing its intent to offer convertible senior notes after the closing bell last night. Acorda Therapeutics Inc. (NASDAQ:ACOR) net profit margin is 5.30% and weekly performance is -6.49%. On last trading day company shares ended up $32.12. Analysts mean target price for the company is $40.35. Acorda Therapeutics Inc. (NASDAQ:ACOR) distance from 50-day simple moving average (SMA50) is -4.72%.